Screener
Eikon Therapeutics, Inc. EIKN Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216791
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from issuance of common stock under stock plans | 277 | 21 |
| Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs | — | 350,213 |
| Proceeds from initial public offering, net of issuance costs | 349,031 | — |
| Net cash provided by financing activities | 349,308 | 350,234 |
| Net increase in cash, cash equivalents and restricted cash | 56,290 | 81,859 |
| Cash, cash equivalents and restricted cash at beginning of period | 113,072 | 130,878 |
| Cash, cash equivalents and restricted cash at end of period | $169,362 | $212,737 |
| Cash, cash equivalents and restricted cash at end of period |
Item 1. Condensed Financial Statements (Unaudited).
FAQ
- What is Eikon Therapeutics, Inc.'s financing cash flow?
- Eikon Therapeutics, Inc. (EIKN) reported financing cash flow of $349.31M in Q1 2026.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Eikon Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude